Tapentadol immediate-release for acute pain

References

• Shavit Y, Fridel K, Beilin B. Postoperative pain management and proinflammatory cytokines: animal and human studies. J. Neuroimmune Pharmacol.1(4), 443–451 (2006).
   PubMed Web of Science ®Google Scholar
• Pogatzki-Zahn EM, Zahn PK. From preemptive to preventive analgesia. Curr. Opin. Anaesthesiol.19(5), 551–555 (2006).
   Google Scholar
• Moore RA, McQuay HJ. Prevalence of opioid adverse events in chronic non-malignant pain: systematic review of randomized trials of oral opioids. Arthritis Res. Ther.7, R1046–R1051 (2005).
   PubMed Web of Science ®Google Scholar
• Pergolizzi J, Böger RH, Budd K et al. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone). Pain Pract.8(4), 287–313 (2008).
   PubMedGoogle Scholar
• Hartrick CT. Multimodal postoperative pain management. Am. J. Health Syst. Pharm.61(Suppl. 1), S4–S10 (2004).
   Google Scholar
• Wheeler M, Oderda GM, Ashburn MA, Lipman AG. Adverse effects associated with postoperative opioid analgesia: a systematic review. J. Pain3, 159–180 (2002).
   PubMed Web of Science ®Google Scholar
• Gaskell H, Derry S, Moore RA, McQuay HJ. Single dose oral oxycodone and oxycodone plus paracetamol (acetaminophen) for acute postoperative pain in adults. Cochrane Database Syst. Rev.3, CD002763 (2009).
   Google Scholar
• Toms L, Derry S, Moore RA, McQuay HJ. Single dose oral paracetamol (acetaminophen) with codeine for postoperative pain in adults. Cochrane Database Syst. Rev.1, CD001547 (2009).
   Google Scholar
• Myers RP, Shaheen AA, Li B, Dean S, Quan H. Impact of liver disease, alcohol abuse, and unintentional ingestions on the outcomes of acetaminophen overdose. Clin. Gastroenterol. Hepatol.6(8), 918–925 (2008).
   PubMed Web of Science ®Google Scholar
• Gan TJ, Lubarsky DA, Flood EM et al. Patient preferences for acute pain treatment. Br. J. Anaesth.92(5), 681–688 (2004).
   PubMed Web of Science ®Google Scholar
• Revees RR, Burke RS. Tramadol: basic pharmacology and emerging concepts. Drugs Today (Barc.)44(11), 827–836 (2008).
   Google Scholar
• Raffa RB, Friderichs E. The basic science aspect of tramadol hydrochloride. Pain Rev.3, 249–271 (1996).
   Google Scholar
• Epstein DH, Preston KL, Jasinski DR. Abuse liability, behavioral pharmacology, and physical-dependence potential of opioids in humans and laboratory animals: lessons from tramadol. Biol. Psychol.73, 90–99 (2006).
   PubMed Web of Science ®Google Scholar
• Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin. Pharmacol. Ther.60, 636–644 (1996).
   PubMed Web of Science ®Google Scholar
• Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin. Pharmacokinet.48(12), 761–804 (2009).
   PubMed Web of Science ®Google Scholar
• Foster A, Mobley E, Wang Z. Complicated pain management in a CYP450 2D6 poor metabolizer. Pain Pract.7(4), 352–356 (2007).
   PubMedGoogle Scholar
• Tzschentke TM, De Vry J, Terlinden R et al. Tapentadol hydrochloride: analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor. Drugs Future31(12), 1053–1061 (2006).
   Web of Science ®Google Scholar
• Tzschentke TM, Christoph T, Kögel B et al. (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J. Pharmacol. Exp. Ther.323(1), 265–276 (2007).
   PubMed Web of Science ®Google Scholar
• Hartrick CT. Tapentadol immediate release for the relief of moderate-to-severe acute pain. Expert Opin. Pharmacother.10(16), 2687–2696 (2009).
   PubMed Web of Science ®Google Scholar
• Monory K, Greiner E, Sartania N et al. Opioid binding profiles of new hydrazone, oxime, carbazone and semicarbazone derivatives of 14-alkoxymorphinans. Life Sci.64(22), 2011–2020 (1999).
   PubMedGoogle Scholar
• Terlinden R, Ossig J, Fliegert F, Lange C, Göhler K. Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. Eur. J. Drug Metab. Pharmacokinet.32(3), 163–169 (2007).
   PubMed Web of Science ®Google Scholar
• Lötsch J, Weiss M, Ahne G, Kobal G, Geisslinger G. Pharmacokinetic modeling of M6G formation after oral administration of morphine in healthy volunteers. Anesthesiology90(4), 1026–1038 (1999).
   PubMedGoogle Scholar
• Kneip C, Terlinden R, Beier H, Chen G. Investigations into drug–drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab. Lett.2, 67–75 (2008).
   PubMedGoogle Scholar
• Smit JW, Oh C, Rengelshausen J et al. Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug–drug interaction studies. Pharmacotherapy30(1), 25–34 (2010).
   PubMed Web of Science ®Google Scholar
• Mangold B, Oh C, Jaeger D et al. The pharmacokinetics of tapentadol are not affected by omeprazole: results of a 2-way crossover drug-interaction study in healthy subjects. Pain Pract.7(S1), 55 (2007).
   Google Scholar
• Smit J, Oh C, Mangold B et al. Effects of metoclopramide on tapentadol pharmacokinetics: results of an open-label, cross-over, drug–drug interaction study. J. Clin. Pharmacol.49, 1104 (2009) (Abstract 62).
   Google Scholar
• Smit J, Oh C, Lannie C et al. Effects of probenecid on tapentadol immediate release pharmacokinetics: results of an open-label, crossover, drug–drug interaction study. J. Clin. Pharmacol.49, 1104 (2009) (Abstract 61).
   Google Scholar
• Gardner JS, Blough D, Drinkard CR et al. Tramadol and seizures: a surveillance study in a managed care population. Pharmacotherapy20(12), 1423–1431 (2000).
   PubMed Web of Science ®Google Scholar
• Kleinert R, Lange C, Steup A et al. Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. Anesth. Analg.107(6), 2048–2055 (2008).
   PubMed Web of Science ®Google Scholar
• Stegmann JU, Weber H, Steup A et al. The efficacy and tolerability of multiple-dose tapentadol immediate release for the relief of acute pain following orthopedic (bunionectomy) surgery. Curr. Med. Res. Opin.24(11), 3185–3196 (2008).
   PubMed Web of Science ®Google Scholar
• Daniels SE, Upmalis D, Okamoto A, Lange C, Häeussler J. A randomized, double-blind, Phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. Curr. Med. Res. Opin.25(3), 765–776, (2009).
   PubMed Web of Science ®Google Scholar
• Daniels S, Casson E, Stegmann JU et al. A randomized, double-blind, placebo-controlled Phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. Curr. Med. Res. Opin.25(6), 1551–1561 (2009).
   PubMed Web of Science ®Google Scholar
• Hartrick C, Van Hove I, Stegmann JU, Oh C, Upmalis D. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, Phase III, randomized, double-blind, active- and placebo-controlled study. Clin. Ther.31(2), 260–271 (2009).
   PubMed Web of Science ®Google Scholar
• Hale M, Upmalis D, Okamoto A, Lange C, Rauschkolb C. Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. Curr. Med. Res. Opin.25(5), 1095–1104 (2009).
   PubMed Web of Science ®Google Scholar
• Upmalis D, Lange C, Okamoto A et al. A pooled analysis of the incidence of treatment-emergent adverse events in Phase 2/3 studies of tapentadol IR. Pain Pract.9(S1), 163 (2009).
   Google Scholar
• Wesson DR, Ling W. The Clinical Opiate Withdrawal Scale (COWS). J. Psychoactive Drugs35(2), 253–259 (2003).
   PubMed Web of Science ®Google Scholar
• Handelsman L, Cochrane KJ, Aronson MJ et al. Two new rating scales for opiate withdrawal. Am. J. Drug Alcohol Abuse13(3), 293–308 (1987).
   PubMed Web of Science ®Google Scholar
• Antman EM, Bennett JS, Daugherty A, Furberg C, Roberts H, Taubert KA. Use of nonsteroidal anti-inflammatory drugs: an update for clinicians. A scientific statement from the American Heart Association. Circulation115, 1634–1642 (2007).
   PubMed Web of Science ®Google Scholar
• Tannenbaum H, Bombardier C, Davis P, Russell AS; Third Canadian Consensus Conference Group. An evidence-based approach to prescribing nonsteroidal anti-inflammatory drugs. Third Canadian Consensus Conference. J. Rheumatol.33, 140–157 (2006).
   PubMed Web of Science ®Google Scholar
• Desai SP, Solomon DH, Abramson SB et al. The American College of Rheumatology Ad Hoc Group on Use of Selective and Nonselective Nonsteroidal Anti-inflammatory Drugs. Recommendations for the use of selective and non-selective anti-inflammatory drugs: an American College of Rheumatology white paper. Arthritis Rheum.59, 1058–1073 (2008).
   PubMed Web of Science ®Google Scholar
• AGS Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J. Am. Geriatr. Soc.57(8), 1331–1346 (2009).
   PubMed Web of Science ®Google Scholar
• Kuehn BM. New pain guideline for older patients: avoid NSAIDs, consider opioids. JAMA302, 19 (2009).
   PubMed Web of Science ®Google Scholar
• Avouac J, Gossec L, Dougados M. Efficacy and safety of opioids for osteoarthritis: a meta-analysis of randomized controlled trials. Osteoarthritis Cartilage15, 957–965 (2007).
   PubMed Web of Science ®Google Scholar
• Leandro G. Meta-analysis in Medical Research. Blackwell Publishing, Ltd, Malden, MA, USA (2005).
   Google Scholar